产品说明书
Enoximone
 |
同义名 : | 烯氟酮 ;MDL 17043 |
| CAS号 : | 77671-31-9 | |
| 货号 : | A414763 | |
| 分子式 : | C12H12N2O2S | |
| 纯度 : | 98%+ | |
| 分子量 : | 248.301 | |
| MDL号 : | MFCD00867130 | |
| 存储条件： |
粉末 Sealed in dry,Room Temperature 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 7 mg/mL(28.19 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation. The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation[1]. Enoximone sulphoxide has the same inotropic and vasodilator activities as enoximone but is 0.13-0.14 times as potent and has a 13 times longer duration of inotropic action in the dog[2]. Early intervention with the selective PDE3-inhibitor enoximone may help to revert respiratory failure as well as avert mechanical ventilation, and reduces ICU/hospital time in patients with severe SARS-CoV-2 pneumonia[4]. Twelve weeks of treatment with low-dose enoximone improves exercise capacity in patients with CHF(chronic heart failure), without increasing adverse events[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT03772990 | Cardiac Surgery ... 展开 >> Cardiopulmonary Bypass 收起 << | Phase 4 | Not yet recruiting | March 30, 2022 | - |
| NCT01864252 | Myocardial Reperfusion Injury | Phase 3 | Unknown | February 2016 | United Kingdom ... 展开 >> The Heart Hospital, UCL Hospitals NHS Trust Recruiting London, United Kingdom, NW1 2PG Contact: Ashraf Hamarneh, MBchB,MRCP 02034479781 a.hamarneh@ucl.ac.uk Principal Investigator: Derek M Yellon, PhD DSc FACC Principal Investigator: Derek J Hausenloy, MD PhD FRCP Sub-Investigator: Ashraf Hamarneh, MBchB MRCP Sub-Investigator: Shyam Kolvekar, MS MCh FRCS Sub-Investigator: Roger Cordery, BSc FRCA Sub-Investigator: Vivek Sivaraman, MRCP MD FRCA 收起 << |
| NCT00484133 | Severe Sepsis ... 展开 >> Microcirculation 收起 << | Phase 4 | Unknown | - | Netherlands ... 展开 >> Onze Lieve Vrouwe Gasthuis, intensive care Recruiting Amsterdam, Netherlands, 1090 HM Contact: Rutger v Raalte, MD 0031205993007 R.vanRaalte@olvg.nl Principal Investigator: Rutger v Raalte, MD 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.03mL 0.81mL 0.40mL |
20.14mL 4.03mL 2.01mL |
40.27mL 8.05mL 4.03mL |
| 参考文献 |
|---|